Sanofi: No big exodus from Genzyme; Soligenix pockets $5M upfront;

@FierceBiotech: FDA cites "corrupt" CRO for widespread falsification. News | Follow @FierceBiotech

@JohnCFierce: BMS R&D expenses up 12% in Q2, to $923M; won't be any complaints on that score with net sales rising. | Follow @JohnCFierce

@MaureenFierce: E&Y: Biotech jobs on the rise in US, but pressures on business model have increased to extraordinary levels. Report | Follow @MaureenFierce

@RyanMFierce: Broad Institute CIO presents a case for injecting video game elements into biotech R&D: Item | Follow @RyanMFierce

> Sanofi CEO Chris Viehbacher says that the pharma company has managed to avert any exodus of top execs from Genzyme. The two companies have "very different cultures," Viehbacher noted, but Sanofi has been working hard to bridge their differences. Story

> Princeton, NJ-based Soligenix says it has pocketed a $5 million upfront after expanding and amending its North American licensing partnership with Sigma-Tau Pharmaceuticals for orBec (oral beclomethasone dipropionate or Oral BDP) into the European territory. In addition, Sigma-Tau promised up to $11 million in milestones. Release

> CytRx ($CYTR) has priced a $20.4 million offering. CytRx release

Pharma News

@FiercePharma: DoJ subpoenas AZ, Medco about four meds. Story | Follow @FiercePharma

> High court ruling solves generics liability suit. News

> AZ raises forecast, slaps premium price on Brilinta. Article

> Tax, antitrust issues push Pfizer towards spinoff. Report

Manufacturing News

> Indianapolis strengthens hold as cold chain hub. Item

> UN conference names Catalent top CMO. Piece

> GSK adds consumer savvy to procurment role. Article

> Russia plots API production conquest. Report

> DB Schenker rolls out RFID temp-monitoring service. Story

> Millipore: single-use plus lean cuts time and materials. News

Vaccine News

> Orelli: BioSante melanoma deal could be better. News

> Sanofi taps Leukocare for vaccine stabilization. Story

> Collins: universal flu vax will be achieved in 5 years. More

> CEVEC raises $8.5M to commercialize protein, vaccine platform. Article

> Chicken pox vaccine reduces deaths. Report

And Finally... Researchers at Yale say they know why memory worsens with age, and they suggested a way to repair the breakdown of neural networks in the brain. Release

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.